Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Buying back in heavily today, I got it wrong, partner deals clearly very close or they would not have put out a statement saying no more dilution expected, they cannot legally do that unless partner deals are very well advanced or it would not have got approved by nomad
Well still no rns… and still no TR1 from Lanstead so I wonder who the seller was! EGM will need to be called to raise at these low levels but as Lanstead are majority holder they would support it imo as they can sell at any price given the structure of the death spiral agreement, could get very messy
She’s non executive so would not be involved in placing discussions imo, she’s always going to talk positively about the company that’s her job but that doesn’t stop the share price from falling, Lanstead is the biggest issue here and has been since the first 11p placing, it’s called death spiral for a reason
They are preparing the final results so they will imo need to raise funds beforehand, it’s clear the market knows what’s coming here, if no rns tomorrow after the total price collapse the silence will speak volumes. Avion would simply pick up the IP from the administrators if this went bust, happened at DDDD the assets just got sold off because they couldn’t fund the cash burn… they are hardly going to support IMM over the next 3 years in every placing, they didn’t take any in the last two placings…. IMO they should mothball all R&D work now and just run as a shell company to save cash this cash burn at this Mcap level is unsustainable
Has it been market shenanigans for the last month or has it been Lanstead selling down and the market knowing a placing is imo needed to avoid administration? Lanstead still have 16% to sell probably a bit less if it has been them selling today but this is imo impossible to invest in atm due to the state of the biotech market for fund raises, can easily be forced to take a 50% discount, all well and good having £700k worth of aquis listed incanthera shares but who will buy them all because they can’t sell them on aquis there is no volume. As I have said they are imo in a very bad place and the radio silence despite the share price action is a huge red flag imo
Is it’s a coincidence that yesterday 3 new posters with 0 previous posts come on this board and start trying to ramp it… the very next day the price tanks almost as if they knew something bad was on the way and needed to get out….
They have put themselves in a very sticky situation now, they can’t use Lanstead imo as even raising £500k via Lanstead at this level would put them over the formal takeover level which as a death spiral finance provider they would not ever do. Any normal placing would clearly imo be at a huge discount as the market for biotech placings is beyond appealing right now and the market knows they need cash asap, but who would take a placing knowing Lanstead can and will dump 16% at any price so even if the placing was at 0.5p Lanstead would still sell its holding as that’s the agreement they are a finance provider. And before a professor Alex starts saying I should be sectioned this is all in my opinion based on price action and the previous 3 years cash burn and Lanstead agreement information
All well and good using fancy language, Adastra and Oscar used fancy words all the down from 5p… R&D expenditure was £800k in the previous 6 months, admin costs were £400k. In the placing they received £480k in total, the £1m was a death spiral agreement over 24 months at 2.6p benchmark current price is 1p. IMO they are definitely not well funded into 2024, anyway we shall soon see who is right not that it really matters but ignore price action at your peril and that will be my final remark
I’m fairly confident the good professor will apologise or not post again… it’s all speculation nothing is fact either positive or negative, but for all he knows I could be going through a severe depression and ridiculing mental health is what can tip ppl over the edge, the professor should be better informed before making personal attacks
29th November 2021 - 2:48 pm
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is very pleased to announce that it has signed a 2-year collaboration agreement with Imperial College London.
Alex bottle from Imperial college London professor….
Ridiculing people’s mental health online… won’t go down great at the college I’m sure
Meeting up for a chat is a threat is it? Oh right ok then, no you ridiculed my mental health so I want to discuss that with you, so as I said send me contact info please as I very much doubt your real name is Alex bottlier
I discuss the company and speculate what might happen that’s it, to start ridiculing someone’s mental health is out of order so I suggest you either send me an email address or phone number in your next post or I’ll provide you with mine